1
|
Shen Y, Cui SJ, Chen H, Shen L, Wang M, Dong X, Xiao CJ, Jiang B. Antimalarial Eudesmane Sesquiterpenoids from Dobinea delavayi. J Nat Prod 2020; 83:927-936. [PMID: 32233487 DOI: 10.1021/acs.jnatprod.9b00761] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Eleven new angeloylated eudesmane sesquiterpenoids, dobinins D-N (2, 3, 5, 6, 8, 9, and 11-15), and four known compounds (1, 4, 7, and 10) were isolated from the roots of Dobinea delavayi. A new oxidation product (8a) was also obtained from dobinin H (8). Their structures were elucidated by spectroscopic data and single-crystal X-ray diffraction analyses. Dobinins K-N (12-15) are the first examples of rearrangement noreudesmane analogue sesquiterpenoids with a unique 6/5-fused carbon skeleton. A putative biosynthetic pathway of compounds 12-15 is proposed. Compound 12 exhibited significant antimalarial activity superior to artemisinin with the inhibition ratio of 59.1%, and compounds 3, 5, and 15 exhibited moderate antimalarial activities against Plasmodium yoelii BY265RFP with inhibition ratios ranging from 14.5% to 18.5% at a dose of 30 mg/kg/day. In addition, the apoptosis of P. yoelii BY265RFP by the depolarization of mitochondrial membrane potential with striking ROS production, after parasitized erythrocyte lysis mediated by cytokines IL-12 and IFN-γ, may be a possible mechanism of antimalarial action of compound 12 against P. yoelii BY265RFP.
Collapse
|
2
|
Ernest M, Hunja C, Arakura Y, Haraga Y, Abkallo HM, Zeng W, Jackson DC, Chua B, Culleton R. The Toll-Like Receptor 2 agonist PEG-Pam 2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites. Int J Parasitol Drugs Drug Resist 2018; 8:451-458. [PMID: 30396012 PMCID: PMC6216107 DOI: 10.1016/j.ijpddr.2018.10.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 09/14/2018] [Accepted: 10/22/2018] [Indexed: 01/30/2023]
Abstract
Both vaccine and therapeutic approaches to malaria are based on conventional paradigms; whole organism or single antigen epitope-based vaccines administered with or without an adjuvant, and chemotherapeutics (anti-malaria drugs) that are toxic to the parasite. Two major problems that limit the effectiveness of these approaches are i) high levels of antigenic variation within parasite populations rendering vaccination efficacy against all variants difficult, and ii) the capacity of the parasite to quickly evolve resistance to drugs. We describe a new approach to both protection from and treatment of malaria parasites that involves the direct stimulation of the host innate immune response through the administration of a Toll-Like Receptor-2 (TLR2) agonist. The activity of PEG-Pam2Cys against the hepatocytic stages, erythrocytic stages and gametocytes of the rodent malaria parasite Plasmodium yoelii was investigated in laboratory mice. We show that administration of PEG-Pam2Cys, a soluble form of the TLR2 agonist S-[2,3-bis(palmitoyloxy)propyl] cysteine (Pam2Cys), significantly and dramatically reduces the numbers of malaria parasites that grow in the livers of mice following subsequent challenge with sporozoites. We also show that treatment can also clear parasites from the liver when administered subsequent to the establishment of infection. Finally, PEG-Pam2Cys can reduce the numbers of mosquitoes that are infected, and the intensity of their infection, following blood feeding on gametocytaemic mice. These results suggest that this compound could represent a novel liver stage anti-malarial that can be used both for the clearance of parasites following exposure and for the prevention of the establishment of infection. TLR-2 agonist Pam2Cys reduces malaria parasite burden in the liver when administered prior to sporozoite challenge. It also reduces malaria parasite burden in the liver when administered 24 h after sporozoite challenge. It reduces the transmissibility of a malaria infection to mosquitoes.
Collapse
Affiliation(s)
- Medard Ernest
- Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
| | - Carol Hunja
- Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Yuka Arakura
- Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Yohei Haraga
- Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Hussein M Abkallo
- Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Weiguang Zeng
- Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, 3010, Victoria, Australia
| | - David C Jackson
- Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, 3010, Victoria, Australia; Research Center for Zoonosis Control, Hokkaido University, Sapporo, 001-0020, Japan; Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, 001-0020, Japan
| | - Brendon Chua
- Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, 3010, Victoria, Australia; Research Center for Zoonosis Control, Hokkaido University, Sapporo, 001-0020, Japan; Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, 001-0020, Japan.
| | - Richard Culleton
- Malaria Unit, Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
| |
Collapse
|
3
|
Martí Coma-Cros E, Biosca A, Lantero E, Manca ML, Caddeo C, Gutiérrez L, Ramírez M, Borgheti-Cardoso LN, Manconi M, Fernàndez-Busquets X. Antimalarial Activity of Orally Administered Curcumin Incorporated in Eudragit ®-Containing Liposomes. Int J Mol Sci 2018; 19:E1361. [PMID: 29734652 PMCID: PMC5983818 DOI: 10.3390/ijms19051361] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 04/18/2018] [Accepted: 04/27/2018] [Indexed: 02/01/2023] Open
Abstract
Curcumin is an antimalarial compound easy to obtain and inexpensive, having shown little toxicity across a diverse population. However, the clinical use of this interesting polyphenol has been hampered by its poor oral absorption, extremely low aqueous solubility and rapid metabolism. In this study, we have used the anionic copolymer Eudragit® S100 to assemble liposomes incorporating curcumin and containing either hyaluronan (Eudragit-hyaluronan liposomes) or the water-soluble dextrin Nutriose® FM06 (Eudragit-nutriosomes). Upon oral administration of the rehydrated freeze-dried nanosystems administered at 25/75 mg curcumin·kg−1·day−1, only Eudragit-nutriosomes improved the in vivo antimalarial activity of curcumin in a dose-dependent manner, by enhancing the survival of all Plasmodium yoelii-infected mice up to 11/11 days, as compared to 6/7 days upon administration of an equal dose of the free compound. On the other hand, animals treated with curcumin incorporated in Eudragit-hyaluronan liposomes did not live longer than the controls, a result consistent with the lower stability of this formulation after reconstitution. Polymer-lipid nanovesicles hold promise for their development into systems for the oral delivery of curcumin-based antimalarial therapies.
Collapse
Affiliation(s)
- Elisabet Martí Coma-Cros
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| | - Arnau Biosca
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| | - Elena Lantero
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| | - Maria Letizia Manca
- Department of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Carla Caddeo
- Department of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Lucía Gutiérrez
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| | - Miriam Ramírez
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| | - Livia Neves Borgheti-Cardoso
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| | - Maria Manconi
- Department of Scienze della Vita e dell'Ambiente, Sezione di Scienze del Farmaco, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
| | - Xavier Fernàndez-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
- Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
- Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, ES-08028 Barcelona, Spain.
| |
Collapse
|
4
|
Dhawan S, Gunjan S, Pal A, Tripathi R. Potentiation of antimalarial activity of arteether in combination with Vetiver root extract. Indian J Exp Biol 2016; 54:315-321. [PMID: 27319050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
In malaria, development of resistance towards artemisinin derivatives has urged the need for new drugs or new drug combinations to tackle the drug resistant malaria. We studied the fresh root extract of Vetiver zizanioides (Linn.) Nash (VET) with a CDRI-CIMAP antimalarial α/β arteether (ART) together for their antimalarial potential. Our results showed additive to synergistic antimalarial activity of VET and ART with sum fractional inhibitory concentrations Σ FICs 1.02 ± 0.24 and 1.12 ± 0.32 for chloroquine sensitive (CQS) and chloroquine resistant (CQR) strain of Plasmodium falciparum (William H. Welch), respectively. Further, these combinations were explored against multidrug resistant rodent malaria parasite i.e. P. yoelii nigeriensis. Analysis of in vivo interaction of ART and VET showed that 10 mg/kg x 5 days of ART with 1000 mg/kg of VET x 5 days cured 100% mice infected with MDR parasite, while the same dose of ART could produce only up to 30% cure and VET fraction was not curative at all. Synergism/additiveness, found between VET and ART is reported for the first time. The curative dose of ART in the combination was reduced to its one fourth, and thus limits the side effects, if any. Although antimalarial potential of ART was enhanced by VET, action mechanism of later needs to be elucidated in detail.
Collapse
|
5
|
Parra M, Liu X, Derrick SC, Yang A, Molina-Cruz A, Barillas-Mury C, Zheng H, Thao Pham P, Sedegah M, Belmonte A, Litilit DD, Waldmann TA, Kumar S, Morris SL, Perera LP. Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. PLoS One 2015; 10:e0141141. [PMID: 26505634 PMCID: PMC4624717 DOI: 10.1371/journal.pone.0141141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 10/04/2015] [Indexed: 01/01/2023] Open
Abstract
Malaria remains a major global public health problem with an estimated 200 million cases detected in 2012. Although the most advanced candidate malaria vaccine (RTS,S) has shown promise in clinical trials, its modest efficacy and durability have created uncertainty about the impact of RTS,S immunization (when used alone) on global malaria transmission. Here we describe the development and characterization of a novel modified vaccinia virus Ankara (MVA)–based malaria vaccine which co-expresses the Plasmodium yoelii circumsporozoite protein (CSP) and IL-15. Vaccination/challenge studies showed that C57BL/6 mice immunized with the MVA-CSP/IL15 vaccine were protected significantly better against a P. yoelii 17XNL sporozoite challenge than either mice immunized with an MVA vaccine expressing only CSP or naïve controls. Importantly, the levels of total anti-CSP IgG were elevated about 100-fold for the MVA-CSP/IL15 immunized group compared to mice immunized with the MVA-CSP construct that does not express IL-15. Among the IgG subtypes, the IL-15 expressing MVA-CSP vaccine induced levels of IgG1 (8 fold) and IgG2b (80 fold) higher than the MVA-CSP construct. The significantly enhanced humoral responses and protection detected after immunization with the MVA-CSP/IL15 vaccine suggest that this IL-15 expressing MVA construct could be considered in the development of future malaria immunization strategies.
Collapse
Affiliation(s)
- Marcela Parra
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Xia Liu
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Steven C. Derrick
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Amy Yang
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Alvaro Molina-Cruz
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, 20852, United States of America
| | - Carolina Barillas-Mury
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, 20852, United States of America
| | - Hong Zheng
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Phuong Thao Pham
- Naval Medical Research Center, Silver Spring, MD, 20910, United States of America
| | - Martha Sedegah
- Naval Medical Research Center, Silver Spring, MD, 20910, United States of America
| | - Arnel Belmonte
- Naval Medical Research Center, Silver Spring, MD, 20910, United States of America
| | - Dianne D. Litilit
- Naval Medical Research Center, Silver Spring, MD, 20910, United States of America
| | - Thomas A. Waldmann
- National Cancer Institute, Bethesda, MD, 20892, United States of America
| | - Sanjai Kumar
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Sheldon L. Morris
- Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, 20993, United States of America
| | - Liyanage P. Perera
- National Cancer Institute, Bethesda, MD, 20892, United States of America
- * E-mail:
| |
Collapse
|
6
|
Stickles AM, Ting LM, Morrisey JM, Li Y, Mather MW, Meermeier E, Pershing AM, Forquer IP, Miley GP, Pou S, Winter RW, Hinrichs DJ, Kelly JX, Kim K, Vaidya AB, Riscoe MK, Nilsen A. Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy. Am J Trop Med Hyg 2015; 92:1195-201. [PMID: 25918204 PMCID: PMC4458825 DOI: 10.4269/ajtmh.14-0553] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 02/13/2015] [Indexed: 11/07/2022] Open
Abstract
Single-dose therapies for malaria have been proposed as a way to reduce the cost and increase the effectiveness of antimalarial treatment. However, no compound to date has shown single-dose activity against both the blood-stage Plasmodium parasites that cause disease and the liver-stage parasites that initiate malaria infection. Here, we describe a subset of cytochrome bc1 (cyt bc1) inhibitors, including the novel 4(1H)-quinolone ELQ-400, with single-dose activity against liver, blood, and transmission-stage parasites in mouse models of malaria. Although cyt bc1 inhibitors are generally classified as slow-onset antimalarials, we found that a single dose of ELQ-400 rapidly induced stasis in blood-stage parasites, which was associated with a rapid reduction in parasitemia in vivo. ELQ-400 also exhibited a low propensity for drug resistance and was active against atovaquone-resistant P. falciparum strains with point mutations in cyt bc1. Ultimately, ELQ-400 shows that cyt bc1 inhibitors can function as single-dose, blood-stage antimalarials and is the first compound to provide combined treatment, prophylaxis, and transmission blocking activity for malaria after a single oral administration. This remarkable multi-stage efficacy suggests that metabolic therapies, including cyt bc1 inhibitors, may be valuable additions to the collection of single-dose antimalarials in current development.
Collapse
Affiliation(s)
- Allison M Stickles
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Li-Min Ting
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Joanne M Morrisey
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Yuexin Li
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Michael W Mather
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Erin Meermeier
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - April M Pershing
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Isaac P Forquer
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Galen P Miley
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Sovitj Pou
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Rolf W Winter
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - David J Hinrichs
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Jane X Kelly
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Kami Kim
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Akhil B Vaidya
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Michael K Riscoe
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| | - Aaron Nilsen
- Departments of Physiology and Pharmacology, Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon; Departments of Medicine, Pathology, and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania; VA Medical Center, Portland, Oregon
| |
Collapse
|
7
|
Bertani S, Gantier JC, Chabaud A, Landau I. Action of adrenalin on the circulation of the murinePlasmodiumdeveloping stages, in different blood compartments. Parasite 2014; 11:343-50. [PMID: 15638134 DOI: 10.1051/parasite/2004114343] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Adrenalin was used to investigate in vivo the circulation of the different stages of rodent Plasmodium present in the blood. A single dose of adrenalin injected to mice infected with P. yoelii resulted immediately in i) a diminution of the parasitaemia of approximately 50% in the peripheral large vessels (estimated in tail blood films), as well as in the capillaries (estimated in smears of blood collected from a fed Anopheles), and ii) an increased parasitaemia in blood collected by cardiac puncture from the right heart. The numbers of young stages of P. yoelii in the peripheral blood were initially somewhat reduced but, unexpectedly, midterm trophozoites were preferentially expelled from the peripheral blood into major organs like the heart. With P. vinckei, parasitaemia decreased only when midterm trophozoites predominated, and with P. chabaudi no effect was observed at any time. We propose that midterm trophozoites, by their increased surface area, as compared to rings, and their flexibility which contrasts with the rigid schizonts, are particularly susceptible to haemodynamic perturbations.
Collapse
Affiliation(s)
- S Bertani
- Museum National d'Histoire Naturelle, USM 0307, "Parasitologie Comparée et Modèles Expérimentaux", associée a l'Inserm (UI 567), et Ecole Pratique des Hautes Etudes, 61, rue Buffon, 75005 Paris, France
| | | | | | | |
Collapse
|
8
|
Zhang J, Zhang S, Wang Y, Xu W, Zhang J, Jiang H, Huang F. Modulation of Anopheles stephensi gene expression by nitroquine, an antimalarial drug against Plasmodium yoelii infection in the mosquito. PLoS One 2014; 9:e89473. [PMID: 24586804 PMCID: PMC3933544 DOI: 10.1371/journal.pone.0089473] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2013] [Accepted: 01/22/2014] [Indexed: 12/30/2022] Open
Abstract
Background Antimalarial drugs may impact mosquito’s defense against Plasmodium parasites. Our previous study showed nitroquine significantly reduced infection of Anopheles stephensi by Plasmodium yoelii, but the underlying mechanism remains unclear. In order to understand how transmission capacity of An. stephensi was affected by nitroquine, we explored the transcriptome of adult females after different treatments, examined changes in gene expression profiles, and identified transcripts affected by the drug and parasite. Methodology/Principal Findings We extended massively parallel sequencing and data analysis (including gene discovery, expression profiling, and function prediction) to An. stephensi before and after Plasmodium infection with or without nitroquine treatment. Using numbers of reads assembled into specific contigs to calculate relative abundances (RAs), we categorized the assembled contigs into four groups according to the differences in RA values infection induced, infection suppressed, drug induced, and drug suppressed. We found both nitroquine in the blood meal and Plasmodium infection altered transcription of mosquito genes implicated in diverse processes, including pathogen recognition, signal transduction, prophenoloxidase activation, cytoskeleton assembling, cell adhesion, and oxidative stress. The differential gene expression may have promoted certain defense responses of An. stephensi against the parasite and decreased its infectivity. Conclusions/Significance Our study indicated that nitroquine may regulate several immune mechanisms at the level of gene transcription in the mosquito against Plasmodium infection. This highlights the need for better understanding of antimalarial drug’s impact on parasite survival and transmission. In addition, our data largely enriched the existing sequence information of An. stephensi, an epidemiologically important vector species.
Collapse
Affiliation(s)
- Jian Zhang
- Department of Pathobiology, The Third Military Medical University, Chongqing, P. R. China
| | - Shuguang Zhang
- Department of Entomology and Plant Pathology, Oklahoma State University, Stillwater, Oklahoma, United States of America
| | - Yanyan Wang
- Department of Pathobiology, The Third Military Medical University, Chongqing, P. R. China
| | - Wenyue Xu
- Department of Pathobiology, The Third Military Medical University, Chongqing, P. R. China
| | - Jingru Zhang
- Department of Pathobiology, The Third Military Medical University, Chongqing, P. R. China
| | - Haobo Jiang
- Department of Entomology and Plant Pathology, Oklahoma State University, Stillwater, Oklahoma, United States of America
- * E-mail: (FH); (HJ)
| | - Fusheng Huang
- Department of Pathobiology, The Third Military Medical University, Chongqing, P. R. China
- * E-mail: (FH); (HJ)
| |
Collapse
|
9
|
Stewart LB, Peters W, Robinson BL. The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate. Annals of Tropical Medicine & Parasitology 2013; 98:763-83. [PMID: 15667710 DOI: 10.1179/136485913x13789813917625] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In recent years infection with chloroquine-resistant Plasmodium falciparum has been combatted with two long-acting antimalarials, pyrimethamine and sulfadoxine, in the combination known as Fansidar that exerts a strong, synergistic action on the asexual stages of the parasite. This second-line regimen, however, is failing increasingly because of the selection of resistant clones in endemic areas, and effective, safe, alternative drugs or drug combinations that are also affordable are urgently needed. Antimalarial drugs with shorter half-lives than those of pyrimethamine or sulfadoxine are likely to be slower to select resistant parasites. In the experiments reported here, the baseline in-vivo responses of rodent malarial parasites to chlorproguanil and proguanil and their active metabolites, chlorcycloguanil and cycloguanil, as well as those to dapsone and artesunate, were explored. In general, the most sensitive parasite to all of these compounds was P. chabaudi. When the drugs were used, individually, to select resistance via the '2%-relapse technique', relatively stable resistance to each was obtained in P. chabaudi as well as in P. berghei and P. yoelii ssp. NS, the last of these being also highly resistant to chloroquine. Of most concern was the rapidity and high level of resistance developed by P. chabaudi to artesunate. The experiments also validated the use of chlorcycloguanil or cycloguanil as surrogates for chlorproguanil or proguanil. Further studies to investigate the possible value of administering chlorproguanil-dapsone, with or without artesunate, are under way and will be reported separately.
Collapse
Affiliation(s)
- L B Stewart
- Centre for Tropical Antiprotozoal Chemotherapy, Y Block, Northwick Park Institute for Medical Research, Watford Road, Harrow HA1 3UJ, UK.
| | | | | |
Collapse
|
10
|
Cruz-Gallardo I, Díaz-Moreno I, Díaz-Quintana A, Donaire A, Velázquez-Campoy A, Curd RD, Rangachari K, Birdsall B, Ramos A, Holder AA, De la Rosa MA. Antimalarial activity of cupredoxins: the interaction of Plasmodium merozoite surface protein 119 (MSP119) and rusticyanin. J Biol Chem 2013; 288:20896-20907. [PMID: 23749994 PMCID: PMC3774360 DOI: 10.1074/jbc.m113.460162] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 06/07/2013] [Indexed: 11/06/2022] Open
Abstract
The discovery of effective new antimalarial agents is urgently needed. One of the most frequently studied molecules anchored to the parasite surface is the merozoite surface protein-1 (MSP1). At red blood cell invasion MSP1 is proteolytically processed, and the 19-kDa C-terminal fragment (MSP119) remains on the surface and is taken into the red blood cell, where it is transferred to the food vacuole and persists until the end of the intracellular cycle. Because a number of specific antibodies inhibit erythrocyte invasion and parasite growth, MSP119 is therefore a promising target against malaria. Given the structural homology of cupredoxins with the Fab domain of monoclonal antibodies, an approach combining NMR and isothermal titration calorimetry (ITC) measurements with docking calculations based on BiGGER is employed on MSP119-cupredoxin complexes. Among the cupredoxins tested, rusticyanin forms a well defined complex with MSP119 at a site that overlaps with the surface recognized by the inhibitory antibodies. The addition of holo-rusticyanin to infected cells results in parasitemia inhibition, but negligible effects on parasite growth can be observed for apo-rusticyanin and other proteins of the cupredoxin family. These findings point to rusticyanin as an excellent therapeutic tool for malaria treatment and provide valuable information for drug design.
Collapse
Affiliation(s)
- Isabel Cruz-Gallardo
- From the Instituto de Bioquímica Vegetal y Fotosíntesis (IBVF), cicCartuja, Universidad de Sevilla-CSIC, Avenida Américo Vespucio 49, Sevilla 41092, Spain
| | - Irene Díaz-Moreno
- From the Instituto de Bioquímica Vegetal y Fotosíntesis (IBVF), cicCartuja, Universidad de Sevilla-CSIC, Avenida Américo Vespucio 49, Sevilla 41092, Spain
| | - Antonio Díaz-Quintana
- From the Instituto de Bioquímica Vegetal y Fotosíntesis (IBVF), cicCartuja, Universidad de Sevilla-CSIC, Avenida Américo Vespucio 49, Sevilla 41092, Spain
| | - Antonio Donaire
- the Departamento de Química Inorgánica, Facultad de Química, Universidad de Murcia, Campus Universitario de Espinardo, Murcia 30100, Spain
| | - Adrián Velázquez-Campoy
- the Instituto de Biocomputación y Física de Sistemas complejos (BIFI), Universidad de Zaragoza, c/Mariano Esquillor, Zaragoza 50018, Spain
| | | | | | - Berry Birdsall
- Molecular Structure Division, Medical Research Council (MRC) National Institute for Medical Research, The Ridgeway, Mill Hill, London W7 1AA, United Kingdom
| | - Andres Ramos
- Molecular Structure Division, Medical Research Council (MRC) National Institute for Medical Research, The Ridgeway, Mill Hill, London W7 1AA, United Kingdom
| | | | - Miguel A De la Rosa
- From the Instituto de Bioquímica Vegetal y Fotosíntesis (IBVF), cicCartuja, Universidad de Sevilla-CSIC, Avenida Américo Vespucio 49, Sevilla 41092, Spain,.
| |
Collapse
|
11
|
Parra M, Liu X, Derrick SC, Yang A, Tian J, Kolibab K, Kumar S, Morris SL. Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination. PLoS One 2013; 8:e66115. [PMID: 23861742 PMCID: PMC3701530 DOI: 10.1371/journal.pone.0066115] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2013] [Accepted: 05/01/2013] [Indexed: 12/14/2022] Open
Abstract
Although the effectiveness of BCG vaccination in preventing adult pulmonary tuberculosis (TB) has been highly variable, epidemiologic studies have suggested that BCG provides other general health benefits to vaccinees including reducing the impact of asthma, leprosy, and possibly malaria. To further evaluate whether BCG immunization protects against malarial parasitemia and to define molecular correlates of this non-specific immunity, mice were vaccinated with BCG and then challenged 2 months later with asexual blood stage Plasmodium yoelii 17XNL (PyNL) parasites. Following challenge with PyNL, significant decreases in parasitemia were observed in BCG vaccinated mice relative to naïve controls. To identify immune molecules that may be associated with the BCG-induced protection, gene expression was evaluated by RT-PCR in i) naïve controls, ii) BCG-vaccinated mice, iii) PyNL infected mice and iv) BCG vaccinated/PyNL infected mice at 0, 1, 5, and 9 days after the P. yoelii infection. The expression results showed that i) BCG immunization induces the expression of at least 18 genes including the anti-microbial molecules lactoferrin, eosinophil peroxidase, eosinophil major basic protein and the cathelicidin-related antimicrobial peptide (CRAMP); ii) an active PyNL infection suppresses the expression of important immune response molecules; and iii) the extent of PyNL-induced suppression of specific genes is reduced in BCG-vaccinated/PyNL infected mice. To validate the gene expression data, we demonstrated that pre-treatment of malaria parasites with lactoferrin or the cathelicidin LL-37 peptide decreases the level of PyNL parasitemias in mice. Overall, our study suggests that BCG vaccination induces the expression of non-specific immune molecules including antimicrobial peptides which may provide an overall benefit to vaccinees by limiting infections of unrelated pathogens such as Plasmodium parasites.
Collapse
Affiliation(s)
- Marcela Parra
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Xia Liu
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Steven C. Derrick
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Amy Yang
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Jinhua Tian
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Kristopher Kolibab
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Sanjai Kumar
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
| | - Sheldon L. Morris
- Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
- * E-mail:
| |
Collapse
|
12
|
Azcárate IG, Marín-García P, Camacho N, Pérez-Benavente S, Puyet A, Diez A, Ribas de Pouplana L, Bautista JM. Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin. Br J Pharmacol 2013; 169:645-58. [PMID: 23488671 PMCID: PMC3682711 DOI: 10.1111/bph.12156] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Revised: 01/09/2013] [Accepted: 02/01/2013] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND AND PURPOSE Blood-stage Plasmodium parasites cause morbidity and mortality from malaria. Parasite resistance to drugs makes development of new chemotherapies an urgency. Aminoacyl-tRNA synthetases have been validated as antimalarial drug targets. We explored long-term effects of borrelidin and mupirocin in lethal P. yoelii murine malaria. EXPERIMENTAL APPROACH Long-term (up to 340 days) immunological responses to borrelidin or mupirocin were measured after an initial 4 day suppressive test. Prophylaxis and cure were evaluated and the inhibitory effect on the parasites analysed. KEY RESULTS Borrelidin protected against lethal malaria at 0.25 mg·kg⁻¹·day⁻¹. Antimalarial activity of borrelidin correlated with accumulation of trophozoites in peripheral blood. All infected mice treated with borrelidin survived and subsequently developed immunity protecting them from re-infection on further challenges, 75 and 340 days after the initial infection. This long-term immunity in borrelidin-treated mice resulted in negligible parasitaemia after re-infections and marked increases in total serum levels of antiparasite IgGs with augmented avidity. Long-term memory IgGs mainly reacted against high and low molecular weight parasite antigens. Immunofluorescence microscopy showed that circulating IgGs bound predominantly to late intracellular stage parasites, mainly schizonts. CONCLUSIONS AND IMPLICATIONS Low borrelidin doses protected mice from lethal malaria infections and induced protective immune responses after treatment. Development of combination therapies with borrelidin and selective modifications of the borrelidin molecule to specifically inhibit plasmodial threonyl tRNA synthetase should improve therapeutic strategies for malaria.
Collapse
Affiliation(s)
- I G Azcárate
- Department of Biochemistry and Molecular Biology IV and Research Institute Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Njomnang Soh P, Witkowski B, Gales A, Huyghe E, Berry A, Pipy B, Benoit-Vical F. Implication of glutathione in the in vitro antiplasmodial mechanism of action of ellagic acid. PLoS One 2012; 7:e45906. [PMID: 23029306 PMCID: PMC3461036 DOI: 10.1371/journal.pone.0045906] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Accepted: 08/23/2012] [Indexed: 12/05/2022] Open
Abstract
The search for new antimalarial chemotherapy has become increasingly urgent due to parasite resistance to current drugs. Ellagic acid (EA) is a polyphenol, recently found in various plant products, that has effective antimalarial activity in vitro and in vivo without toxicity. To further understand the antimalarial mechanism of action of EA in vitro, we evaluated the effects of EA, ascorbic acid and N-acetyl-L-cysteine (NAC), alone and/or in combination on the production of reactive oxygen species (ROS) during the trophozoite and schizonte stages of the erythrocytic cycle of P. falciparum. The parasitized erythrocytes were pre-labelled with DCFDA (dichlorofluorescein diacetate). We showed that NAC had no effect on ROS production, contrary to ascorbic acid and EA, which considerably reduced ROS production. Surprisingly, EA reduced the production of the ROS with concentrations (6.6×10−9 − 6.6×10−6 M) ten-fold lower than ascorbic acid (113×10−6 M). Additionally, the in vitro drug sensitivity of EA with antioxidants showed that antiplasmodial activity is independent of the ROS production inside parasites, which was confirmed by the additive activity of EA and desferrioxamine. Finally, EA could act by reducing the glutathione content inside the Plasmodium parasite. This was consolidated by the decrease in the antiplasmodial efficacy of EA in the murine model Plasmodium yoelii- high GSH strain, known for its high glutathione content. Given its low toxicity and now known mechanism of action, EA appears as a promising antiplasmodial compound.
Collapse
|
14
|
Pou S, Winter RW, Nilsen A, Kelly JX, Li Y, Doggett JS, Riscoe EW, Wegmann KW, Hinrichs DJ, Riscoe MK. Sontochin as a guide to the development of drugs against chloroquine-resistant malaria. Antimicrob Agents Chemother 2012; 56:3475-80. [PMID: 22508305 PMCID: PMC3393441 DOI: 10.1128/aac.00100-12] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2012] [Accepted: 04/09/2012] [Indexed: 11/20/2022] Open
Abstract
Sontochin was the original chloroquine replacement drug, arising from research by Hans Andersag 2 years after chloroquine (known as "resochin" at the time) had been shelved due to the mistaken perception that it was too toxic for human use. We were surprised to find that sontochin, i.e., 3-methyl-chloroquine, retains significant activity against chloroquine-resistant strains of Plasmodium falciparum in vitro. We prepared derivatives of sontochin, "pharmachins," with alkyl or aryl substituents at the 3 position and with alterations to the 4-position side chain to enhance activity against drug-resistant strains. Modified with an aryl substituent in the 3 position of the 7-chloro-quinoline ring, Pharmachin 203 (PH-203) exhibits low-nanomolar 50% inhibitory concentrations (IC(50)s) against drug-sensitive and multidrug-resistant strains and in vivo efficacy against patent infections of Plasmodium yoelii in mice that is superior to chloroquine. Our findings suggest that novel 3-position aryl pharmachin derivatives have the potential for use in treating drug resistant malaria.
Collapse
Affiliation(s)
- Sovitj Pou
- VA Medical Center, Portland, Oregon, USA
| | - Rolf W. Winter
- VA Medical Center, Portland, Oregon, USA
- Department of Chemistry, Portland State University, Portland, Oregon, USA
| | | | - Jane Xu Kelly
- VA Medical Center, Portland, Oregon, USA
- Department of Chemistry, Portland State University, Portland, Oregon, USA
| | - Yuexin Li
- VA Medical Center, Portland, Oregon, USA
| | - J. Stone Doggett
- VA Medical Center, Portland, Oregon, USA
- Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA
| | - Erin W. Riscoe
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA
| | | | - David J. Hinrichs
- VA Medical Center, Portland, Oregon, USA
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA
| | - Michael K. Riscoe
- VA Medical Center, Portland, Oregon, USA
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA
- Department of Chemistry, Portland State University, Portland, Oregon, USA
| |
Collapse
|
15
|
Voza T, Miller JL, Kappe SHI, Sinnis P. Extrahepatic exoerythrocytic forms of rodent malaria parasites at the site of inoculation: clearance after immunization, susceptibility to primaquine, and contribution to blood-stage infection. Infect Immun 2012; 80:2158-64. [PMID: 22431651 PMCID: PMC3370592 DOI: 10.1128/iai.00246-12] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2012] [Accepted: 03/12/2012] [Indexed: 02/04/2023] Open
Abstract
Plasmodium sporozoites are inoculated into the skin of the mammalian host as infected mosquitoes probe for blood. A proportion of the inoculum enters the bloodstream and goes to the liver, where the sporozoites invade hepatocytes and develop into the next life cycle stage, the exoerythrocytic, or liver, stage. Here, we show that a small fraction of the inoculum remains in the skin and begins to develop into exoerythrocytic forms that can persist for days. Skin exoerythrocytic forms were observed for both Plasmodium berghei and Plasmodium yoelii, two different rodent malaria parasites, suggesting that development in the skin of the mammalian host may be a common property of plasmodia. Our studies demonstrate that skin exoerythrocytic stages are susceptible to destruction in immunized mice, suggesting that their aberrant location does not protect them from the host's adaptive immune response. However, in contrast to their hepatic counterparts, they are not susceptible to primaquine. We took advantage of their resistance to primaquine to test whether they could initiate a blood-stage infection directly from the inoculation site, and our data indicate that these stages are not able to initiate malaria infection.
Collapse
Affiliation(s)
- Tatiana Voza
- Department of Medical Parasitology, New York University School of Medicine, New York, New York, USA
| | | | | | - Photini Sinnis
- Department of Medical Parasitology, New York University School of Medicine, New York, New York, USA
| |
Collapse
|
16
|
Witkowski B, Lelièvre J, Nicolau-Travers ML, Iriart X, Njomnang Soh P, Bousejra-ElGarah F, Meunier B, Berry A, Benoit-Vical F. Evidence for the contribution of the hemozoin synthesis pathway of the murine Plasmodium yoelii to the resistance to artemisinin-related drugs. PLoS One 2012; 7:e32620. [PMID: 22403683 PMCID: PMC3293827 DOI: 10.1371/journal.pone.0032620] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 02/02/2012] [Indexed: 11/19/2022] Open
Abstract
Plasmodium falciparum malaria is a major global health problem, causing approximately 780,000 deaths each year. In response to the spreading of P. falciparum drug resistance, WHO recommended in 2001 to use artemisinin derivatives in combination with a partner drug (called ACT) as first-line treatment for uncomplicated falciparum malaria, and most malaria-endemic countries have since changed their treatment policies accordingly. Currently, ACT are often the last treatments that can effectively and rapidly cure P. falciparum infections permitting to significantly decrease the mortality and the morbidity due to malaria. However, alarming signs of emerging resistance to artemisinin derivatives along the Thai-Cambodian border are of major concern. Through long-term in vivo pressures, we have been able to select a murine malaria model resistant to artemisinins. We demonstrated that the resistance of Plasmodium to artemisinin-based compounds depends on alterations of heme metabolism and on a loss of hemozoin formation linked to the down-expression of the recently identified Heme Detoxification Protein (HDP). These artemisinins resistant strains could be able to detoxify the free heme by an alternative catabolism pathway involving glutathione (GSH)-mediation. Finally, we confirmed that artemisinins act also like quinolines against Plasmodium via hemozoin production inhibition. The work proposed here described the mechanism of action of this class of molecules and the resistance to artemisinins of this model. These results should help both to reinforce the artemisinins activity and avoid emergence and spread of endoperoxides resistance by focusing in adequate drug partners design. Such considerations appear crucial in the current context of early artemisinin resistance in Asia.
Collapse
Affiliation(s)
- Benoit Witkowski
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
| | - Joel Lelièvre
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
| | - Marie-Laure Nicolau-Travers
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
| | - Xavier Iriart
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
- UMR 152 IRD-UPS, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Patrice Njomnang Soh
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
| | - Fatima Bousejra-ElGarah
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
| | - Bernard Meunier
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
- Palumed, Castanet-Tolosan, France
| | - Antoine Berry
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
- UMR 152 IRD-UPS, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Françoise Benoit-Vical
- CNRS, LCC (Laboratoire de Chimie de Coordination), and Université de Toulouse Paul Sabatier, UPS, INPT, LCC, Toulouse, France
- Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, and Faculté de Médecine de Rangueil, Université de Toulouse Paul Sabatier, Toulouse, France
- * E-mail:
| |
Collapse
|
17
|
Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med 2012; 9:e1001169. [PMID: 22363211 PMCID: PMC3283556 DOI: 10.1371/journal.pmed.1001169] [Citation(s) in RCA: 252] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Accepted: 12/28/2011] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Malaria remains a disease of devastating global impact, killing more than 800,000 people every year-the vast majority being children under the age of 5. While effective therapies are available, if malaria is to be eradicated a broader range of small molecule therapeutics that are able to target the liver and the transmissible sexual stages are required. These new medicines are needed both to meet the challenge of malaria eradication and to circumvent resistance. METHODS AND FINDINGS Little is known about the wider stage-specific activities of current antimalarials that were primarily designed to alleviate symptoms of malaria in the blood stage. To overcome this critical gap, we developed assays to measure activity of antimalarials against all life stages of malaria parasites, using a diverse set of human and nonhuman parasite species, including male gamete production (exflagellation) in Plasmodium falciparum, ookinete development in P. berghei, oocyst development in P. berghei and P. falciparum, and the liver stage of P. yoelii. We then compared 50 current and experimental antimalarials in these assays. We show that endoperoxides such as OZ439, a stable synthetic molecule currently in clinical phase IIa trials, are strong inhibitors of gametocyte maturation/gamete formation and impact sporogony; lumefantrine impairs development in the vector; and NPC-1161B, a new 8-aminoquinoline, inhibits sporogony. CONCLUSIONS These data enable objective comparisons of the strengths and weaknesses of each chemical class at targeting each stage of the lifecycle. Noting that the activities of many compounds lie within achievable blood concentrations, these results offer an invaluable guide to decisions regarding which drugs to combine in the next-generation of antimalarial drugs. This study might reveal the potential of life-cycle-wide analyses of drugs for other pathogens with complex life cycles.
Collapse
Affiliation(s)
- Michael Delves
- Department of Life Sciences, Imperial College London, London, United Kingdom
| | - David Plouffe
- Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
| | - Christian Scheurer
- Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Stephan Meister
- The Scripps Research Institute, La Jolla, California, United States of America
| | - Sergio Wittlin
- Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Elizabeth A. Winzeler
- Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
- The Scripps Research Institute, La Jolla, California, United States of America
| | - Robert E. Sinden
- Department of Life Sciences, Imperial College London, London, United Kingdom
| | - Didier Leroy
- Medicines for Malaria Venture, Geneva, Switzerland
| |
Collapse
|
18
|
Abstract
CONTEXT Novel antimalarial agents are in demand due to the emergence of multidrug resistant strains. Ginseng, a medicinal plant with antiparasitic activity, contains components that can be used to treat the tropical disease malaria. OBJECTIVE Ginsenosides and polysaccharides are active components of ginseng. This study aimed to elucidate the ability of these compounds to inhibit the replication of Plasmodium yoelii in an attempt to determine whether the medicinal uses of ginseng are supported by pharmacological effects. New antimalarial compounds may be developed from ginsenosides and water-soluble ginseng polysaccharides (WGP). MATERIALS AND METHODS Ginsenosides and ginseng polysaccharides were prepared from ginseng. Antimalarial activities were examined by 4-day tests and repository tests. Macrophage phagocytosis was tested in normal and malaria-bearing mice. RESULTS Ginseng polysaccharides could inhibit residual malaria infection. After a 6-day treatment, the parasitemia reductions of WGP and acidic ginseng polysaccharide (WGPA) were 55.66% and 64.73% at 200 mg/kg/day, respectively. Ginsenosides showed significant antimalarial activity on early infection. Protopanaxadiol-type ginsenosides caused 70.97% chemosuppression at 50 mg/kg/day, higher than 52.8% of total ginsenosides at the same dose. DISCUSSION AND CONCLUSION Protopanaxadiol-type ginsenosides have remarkably suppressive activity during early infection, while acidic ginseng polysaccharides have significant prophylactic activity against malaria by stimulating the immune system. We propose that the activity of ginsenosides is dependent upon non-specific carbohydrate interactions and that the activity of ginseng polysaccharides is due to immunological modulation. Ginsenosides and ginseng polysaccharides might have a potential application in antimalarial treatments.
Collapse
Affiliation(s)
- Han Han
- School of Life Sciences, Northeast Normal University, Changchun, PR China
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Meredith JM, Basu S, Nimmo DD, Larget-Thiery I, Warr EL, Underhill A, McArthur CC, Carter V, Hurd H, Bourgouin C, Eggleston P. Site-specific integration and expression of an anti-malarial gene in transgenic Anopheles gambiae significantly reduces Plasmodium infections. PLoS One 2011; 6:e14587. [PMID: 21283619 PMCID: PMC3026776 DOI: 10.1371/journal.pone.0014587] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2010] [Accepted: 12/30/2010] [Indexed: 01/17/2023] Open
Abstract
Diseases transmitted by mosquitoes have a devastating impact on global health and this is worsening due to difficulties with existing control measures and climate change. Genetically modified mosquitoes that are refractory to disease transmission are seen as having great potential in the delivery of novel control strategies. Historically the genetic modification of insects has relied upon transposable elements which have many limitations despite their successful use. To circumvent these limitations the Streptomyces phage phiC31 integrase system has been successfully adapted for site-specific transgene integration in insects. Here, we present the first site-specific transformation of Anopheles gambiae, the principal vector of human malaria. Mosquitoes were initially engineered to incorporate the phiC31 targeting site at a defined genomic location. A second phase of genetic modification then achieved site-specific integration of Vida3, a synthetic anti-malarial gene. Expression of Vida3, specifically in the midgut of bloodfed females, offered consistent and significant protection against Plasmodium yoelii nigeriensis, reducing average parasite intensity by 85%. Similar protection was observed against Plasmodium falciparum in some experiments, although protection was inconsistent. In the fight against malaria, it is imperative to establish a broad repertoire of both anti-malarial effector genes and tissue-specific promoters for their expression, enabling those offering maximum effect with minimum fitness cost to be identified. In the future, this technology will allow effective comparisons and informed choices to be made, potentially leading to complete transmission blockade.
Collapse
Affiliation(s)
- Janet M. Meredith
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
| | - Sanjay Basu
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
- Department of Entomology, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America
| | - Derric D. Nimmo
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
- Oxitec Ltd, Milton Park, Oxford, United Kingdom
| | - Isabelle Larget-Thiery
- Institut Pasteur, Center for Production and Infection of Anopheles, Parasitology and Mycology Department, Paris, France
| | - Emma L. Warr
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
| | - Ann Underhill
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
| | - Clare C. McArthur
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
| | - Victoria Carter
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
| | - Hilary Hurd
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
| | - Catherine Bourgouin
- Institut Pasteur, Center for Production and Infection of Anopheles, Parasitology and Mycology Department, Paris, France
| | - Paul Eggleston
- Centre for Applied Entomology and Parasitology, Keele University, Keele, United Kingdom
- * E-mail: .
| |
Collapse
|
20
|
Okeola VO, Adaramoye OA, Nneji CM, Falade CO, Farombi EO, Ademowo OG. Antimalarial and antioxidant activities of methanolic extract of Nigella sativa seeds (black cumin) in mice infected with Plasmodium yoelli nigeriensis. Parasitol Res 2010; 108:1507-12. [PMID: 21153838 DOI: 10.1007/s00436-010-2204-4] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2010] [Accepted: 11/27/2010] [Indexed: 11/30/2022]
Abstract
The antimalarial and antioxidant activities of methanolic extract of Nigella sativa seeds (MENS) were investigated against established malaria infection in vivo using Swiss albino mice. The antimalarial activity of the extract against Plasmodium yoelli nigeriensis (P. yoelli) was assessed using the Rane test procedure. Chloroquine (CQ)-treated group served as positive control. The extract, at a dose of 1.25 g/kg body weight significantly (p<0.05) suppressed P. yoelli infection in the mice by 94%, while CQ, the reference drug, produced 86% suppression when compared to the untreated group after the fifth day of treatment. P. yoelli infection caused a significant (p<0.05) increase in the levels of red cell and hepatic malondialdehyde (MDA), an index of lipid peroxidation (LPO) in the mice. Serum and hepatic LPO levels were increased by 71% and 113%, respectively, in the untreated infected mice. Furthermore, P. yoelli infection caused a significant (p<0.05) decrease in the activities of superoxide dismutase, catalase, glutathione-S-transferase and the level of reduced glutathione in tissues of the mice. Treatment with MENS significantly (p<0.05) attenuated the serum and hepatic MDA levels in P. yoelli-infected mice. In addition, MENS restored the activities of red cell antioxidant enzymes in the infected mice to near normal. Moreover, MENS was found to be more effective than CQ in parasite clearance and, in the restoration of altered biochemical indices by P. yoelli infection. These results suggest that N. sativa seeds have strong antioxidant property and, may be a good phytotherapeutic agent against Plasmodium infection in malaria.
Collapse
Affiliation(s)
- Valeelat O Okeola
- Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | | | | | | | | | | |
Collapse
|
21
|
Chen Y, Li S, Sun F, Han H, Zhang X, Fan Y, Tai G, Zhou Y. In vivo antimalarial activities of glycoalkaloids isolated from Solanaceae plants. Pharm Biol 2010; 48:1018-24. [PMID: 20731554 DOI: 10.3109/13880200903440211] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
CONTEXT Malaria is one of the most common and serious protozoan tropical diseases. Multi-drug resistance remains pervasive, necessitating the continuous development of new antimalarial agents. OBJECTIVE Many glycosides, such as triterpenoid saponins, were shown to have antimalarial activity against Plasmodium falciparum in vitro. This study was to elucidate the ability of five glycoalkaloids against Plasmodium yoelii and develop new antimalarial lead compounds. MATERIALS AND METHODS Glycoalkaloids were isolated from three kinds of Solanaceae plants: chaconine and solanine were isolated from Solanum tuberosum L. sprouts, solamargine and solasonine from Solanum nigrum L. fruit, tomatine from Lycopersicon esculentum Mill. fruit. The five isolated glycoalkaloids were evaluated against Plasmodium yoelii 17XL in mice with 4-day parasitemia suppression test in different concentrations. RESULTS Chaconine showed a dose-dependent suppression of malaria infection, ED50, 4.49 mg/kg; therapeutic index (TI), approximately 9. At a dose of 7.50 mg/kg, the parasitemia suppressions of chaconine, tomatine, solamargine, solasonine and solanine were 71.38, 65.25, 64.89, 57.47 and 41.30%, respectively. At 3.75 mg/kg, the parasitemia suppression of chaconine was 42.66%, but the derivative, chaconine-6-O-sulfate, appeared to show no antimalarial activity. Simultaneous administration of chaconine and solanine in 1:1 did not show any synergistic effects. DISCUSSION AND CONCLUSION The results showed that the glycoalkaloids with chacotriose (chaconine and solamargine) were more active than those with solatriose (solanine and solasonine). Chaconine was the most active among the five glycoalkaloids. We propose that the activity is dependent upon non-specific carbohydrate interactions. The 6-OH of chaconine is important for antimalarial activity.
Collapse
Affiliation(s)
- Yan Chen
- School of Life Sciences, Northeast Normal University, Changchun 130024, China
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Zhang J, Huang FS, Xu WY, Wang Y, Zhou TL, Duan JH. Plasmodium yoelii: correlation of TEP1 with mosquito melanization induced by nitroquine. Exp Parasitol 2010; 127:52-7. [PMID: 20599985 DOI: 10.1016/j.exppara.2010.06.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Revised: 06/15/2010] [Accepted: 06/28/2010] [Indexed: 11/17/2022]
Abstract
The antimalarial drug nitroquine is not only an effective antimalarial drug, it is also able to induce the melanization of Plasmodium species. However, the molecular mechanisms of the recognition reaction induced by this drug remain unclear. Silencing of thioester-containing protein-1 (TEP1) significantly compromised the ability of Anopheles gambiae to melanize the Plasmodium, leading to investigation of the involvement of A. stephensi TEP1 in melanization induced by nitroquine. This study shows that (1) binding of AsTEP1 to oocysts, especially melanized oocysts, (2) after ingestion of anti-AsTEP1 antibody, the melanization rate in antibody-treated mosquitoes are significantly lower than in control mosquito (p<0.05). The results suggest that nitroquine is able to induce Plasmodium recognition by TEP1, possibly triggering the resulting melanotic encapsulation. Further elucidation of the molecular mechanisms of mosquito immunity induced by antimalarial drugs will provide theoretical evidence for the use of antimalarial drugs, and a meaningful pathway for the design of novel antimalarial drugs.
Collapse
Affiliation(s)
- Jian Zhang
- Department of the Pathogenic Biology, The Third Military Medical University, Chongqing 400038, PR China.
| | | | | | | | | | | |
Collapse
|
23
|
Ijarotimi SO, Agbedahunsi JM, Onyeji CO, Adewunmi CO. Chemotherapeutic interaction between Khaya grandifoliola (WELW) CDC stem bark extract and two anti-malarial drugs in mice. Afr J Tradit Complement Altern Med 2010; 7:370-6. [PMID: 21731168 PMCID: PMC3005403 DOI: 10.4314/ajtcam.v7i4.56705] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In malarial endemic countries especially in the tropics, conventional antimalarial drugs are used with herbal remedies either concurrently or successively. Khaya grandifoliola is one of such popular herbs used in the treatment of malaria.Various doses of ethanol extract of K. grandifoliola stem bark (50-400 mg/kg/day) were administered orally to Swiss albino mice infected with Plasmodium yoelii nigerense. A dose of 100 mg/kg/day of the extract was also combined with 2.5 mg/kg/day of chloroquine or 6.25 mg/kg/day of halofantrine in both early and established malaria infection test models. The results showed that in the early malaria infection test, K. grandifoliola in combination with chloroquine or halofantrine elicited enhanced antiplasmodial effect in the established infection, there was significantly greater parasite clearance following administration of the combination when compared to the effects of K. grandifoliola or the conventional drugs alone. The mean survival period of parasitized animals was also enhanced by the extract/halofantrine combination. Lower therapeutic doses of halofantrine may be required to potentiate parasite clearance when used in combination with K. grandifoliola. This may constitute great advantage to halofantrine which is associated with cardiotoxicity at high doses.
Collapse
Affiliation(s)
- Steve O Ijarotimi
- Drug Research and Production Unit, Obafemi Awolowo University, Ile-Ife, Nigeria
| | | | | | | |
Collapse
|
24
|
Reis PA, Comim CM, Hermani F, Silva B, Barichello T, Portella AC, Gomes FCA, Sab IM, Frutuoso VS, Oliveira MF, Bozza PT, Bozza FA, Dal-Pizzol F, Zimmerman GA, Quevedo J, Castro-Faria-Neto HC. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. PLoS Pathog 2010; 6:e1000963. [PMID: 20585569 PMCID: PMC2891838 DOI: 10.1371/journal.ppat.1000963] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2009] [Accepted: 05/25/2010] [Indexed: 11/19/2022] Open
Abstract
Neurological impairments are frequently detected in children surviving cerebral malaria (CM), the most severe neurological complication of infection with Plasmodium falciparum. The pathophysiology and therapy of long lasting cognitive deficits in malaria patients after treatment of the parasitic disease is a critical area of investigation. In the present study we used several models of experimental malaria with differential features to investigate persistent cognitive damage after rescue treatment. Infection of C57BL/6 and Swiss (SW) mice with Plasmodium berghei ANKA (PbA) or a lethal strain of Plasmodium yoelii XL (PyXL), respectively, resulted in documented CM and sustained persistent cognitive damage detected by a battery of behavioral tests after cure of the acute parasitic disease with chloroquine therapy. Strikingly, cognitive impairment was still present 30 days after the initial infection. In contrast, BALB/c mice infected with PbA, C57BL6 infected with Plasmodium chabaudi chabaudi and SW infected with non lethal Plasmodium yoelii NXL (PyNXL) did not develop signs of CM, were cured of the acute parasitic infection by chloroquine, and showed no persistent cognitive impairment. Reactive oxygen species have been reported to mediate neurological injury in CM. Increased production of malondialdehyde (MDA) and conjugated dienes was detected in the brains of PbA-infected C57BL/6 mice with CM, indicating high oxidative stress. Treatment of PbA-infected C57BL/6 mice with additive antioxidants together with chloroquine at the first signs of CM prevented the development of persistent cognitive damage. These studies provide new insights into the natural history of cognitive dysfunction after rescue therapy for CM that may have clinical relevance, and may also be relevant to cerebral sequelae of sepsis and other disorders.
Collapse
Affiliation(s)
- Patricia A. Reis
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Clarissa M. Comim
- Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
| | - Fernanda Hermani
- Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
| | - Bruno Silva
- Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
| | - Tatiana Barichello
- Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
| | - Aline C. Portella
- Instituto de Ciências Biomédicas Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Flavia C. A. Gomes
- Instituto de Ciências Biomédicas Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Ive M. Sab
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Valber S. Frutuoso
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Marcus F. Oliveira
- Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Patricia T. Bozza
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Fernando A. Bozza
- Instituto de Pesquisa Clínicas Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Felipe Dal-Pizzol
- Laboratório de Fisiopatologia Experimental, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
| | - Guy A. Zimmerman
- Department of Medicine and Program in Human Molecular Biology and Genetics, University of Utah, Salt Lake City, Utah, United States of America
| | - João Quevedo
- Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Universidade do Extremo Sul Catarinense, Criciúma, Brazil
| | - Hugo C. Castro-Faria-Neto
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- * E-mail:
| |
Collapse
|
25
|
Rungruang T, Boonmars T. In vivo antiparasitic activity of the Thai traditional medicine plant--Tinospora crispa--against Plasmodium yoelii. Southeast Asian J Trop Med Public Health 2009; 40:898-900. [PMID: 19842370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We investigated the in vivo antimalarial effect of crude extract of Tinospora crispa, a Thai traditional medicine plant. Mice were inoculated with Plasmodium yoelii then treated with the crude extract of Tinospora crispa at doses of 20, 40 and 80 mg/kg. Mice receiving the dose of 20 mg/kg died on average on Day 8. Mice remained alive longer when treated of the dose of 40 mg/kg or even longer under the treatment of the dose of 80 mg/kg. Surprisingly and interestingly, one mouse from the group in which the dose of 80 mg/kg was administrated is still alive and the parasite was cleared from the blood stream. In conclusion, T. crispa has an in vivo antimalarial effect in dose dependent manner.
Collapse
Affiliation(s)
- Thanaporn Rungruang
- Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
| | | |
Collapse
|
26
|
Zhang J, Xu WY, Duan JH, Huang FS. [Correlation of Anopheles TEP1 gene with melanization induced by nitroquine]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2009; 27:322-325. [PMID: 20066988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
OBJECTIVE To analyze the relationship between the TEP1 gene of Anopheles stephensi and melanotic encapsulation of Plasmodium yoelii induced by anti-malaria drug nitroquine. METHODS Haemolymph samples from three groups of An. stephensi fed with sucrose solution, Plasmodium-infected blood and nitroquine, respectively, were collected at the 1st, 2nd, 3rd and 4th day after drug administration. Degenerate primers were designed according to the conserved amino acid sequence within TEPs of the mosquitoes. Fluorescent quantitation PCR was used to detect the variation of TEP1 gene transcript induced by nitroquine. The melanization of oocysts was observed by light microscopy. RESULTS TEP1 gene was cloned, the predicted amino acid residues harbored a highly conserved canonical thioester motif GCGEQ. The fluorescent quantitation PCR revealed that nitroquine induced an up-regulation of TEP1 activity. The transcription of TEP1 gene in nitroquine treated group (2.423) was significantly higher than that of the infected blood-fed group(1.036) at the 3rd day after nitroquine treatment (P<0.05). At the same time, most oocysts were found to be encapsulated in nitroquine treated group, while no melanized parasites were observed in the infected blood-fed group. CONCLUSION Transcriptional variation of TEP1 gene may be related to the melanization induced by nitroquine.
Collapse
Affiliation(s)
- Jian Zhang
- Departmnent of Pathogenic Biology, The Third Military Medical University, Chongqing, China
| | | | | | | |
Collapse
|
27
|
Deng S, Hu Y. [Effect of nitroquine on the membrane phospholipid of intraerythrocytic Plasmodium yoelii in vitro]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2009; 17:282-4. [PMID: 12563858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
AIM To study the mechanism of antimalarial action of nitroquine. METHODS Intraerythrocytic P. yoelii was cultured by the method of Trager and Jensen. The amount of [3H]-ethanolamine incorporation was measured as an index of the phospholipid synthesis. DPH was used as a probe to measure the plasmodial fluorescent polarization. RESULTS The incorporation of [3H]-ethanolamine into the P. yoelii infected erthrocytes was markedly inhibited by nitroquine. The plasmodial membrane polarization and viscosity were significantly increased by nitroquine. CONCLUSION Nitroquine could inhibit the phospholipid synthesis and decrease the membrane fluidity of P. yoelii.
Collapse
Affiliation(s)
- S Deng
- Department of Pharmacology, Third Military Medical University, Chongqing 400038
| | | |
Collapse
|
28
|
Chen JD, Zhou TL, Xu WY, Ding Y, Huang FS. [Inhibition of CpG oligodeoxynucleotide on the development of pre-erythrocytic stage of Plasmodium]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2009; 27:1-5. [PMID: 19459490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
OBJECTIVE To study the role of cytidine-phosphate-guanosine oligodeoxynucleotide (CpG ODN) on the development of Plasmodium liver stage. METHODS Plasmodium yoelii BY265 18S rRNA was cloned, and the TaqMan real-time PCR was established on P. yoelii BY265 18S rRNA and mouse GAPDH as quantitative analysis model. The model was tested by the level of liver Plasmodium load with the liver cDNA in BALB/c mice infected by salivary gland sporozoites for 42 hours. Twelve BALB/c mice were randomly divided into CpG group, CpG control group and PBS control group which were injected respectively by ODN1826 30 microg, ODN1826 control 30 microg and 0.01 mol/L PBS 200 microl via vena caudalis. Twenty-four hours later, each mouse was inoculated with 100 sporozoites. Mice were sacrificed in 42 hours after infection, and the liver load of Plasmodium was analyzed by TaqMan real-time PCR. RESULTS The cloned Py BY265 18S rRNA gene showed 98% similarity to Py 17XNL. The quantitative analysis model consisted by 18S rRNA and GAPDH showed positive correlation between the level of liver Plasmodium load and the sporozoite inoculation dose to mice. The Plasmodium load in CpG ODN pre-treated mice was reduced to one fifth of the control group (0.28/1.33) (P<0.05). CONCLUSION The quantitative analysis model of TaqMan RT-PCR can detect the liver load of Plasmodium parasites, and CpG ODN can inhibit the development of its pre-erythrocytic stage.
Collapse
Affiliation(s)
- Ji-de Chen
- Department of Pathogenic Biology, The Third Military Medical University, Chongqing 400038, China
| | | | | | | | | |
Collapse
|
29
|
Ahmad R, Srivastava AK, Tripathi RP, Batra S, Walter RD. Synthesis and biological evaluation of potential modulators of malarial glutathione-S-transferase(s). J Enzyme Inhib Med Chem 2008; 22:327-42. [PMID: 17674815 DOI: 10.1080/14756360601072676] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
Glutathione-S-transferase(s) (E.C.2.5.1.18, GSTs) have been investigated in parasitic protozoans with respect to their biochemistry and they have been identified as potential vaccine candidates in protozoan parasites and as a target in the synthesis of new antiparasitic agents. In a search towards the identification of novel biochemical targets for antimalarial drug design, the area of Plasmodium glutathione metabolism provides a number of promising chemotherapeutic targets. GST activity was determined in various subcellular fractions of malarial parasites Plasmodium yoelii and was found to be localized mainly in the cytosolic fraction (specific activity, c. 0.058 +/- 0.016 micromol/min/mg protein). Hemin, a known inhibitor of mammalian GST(s), maximally inhibited this enzyme from P. yoelii to nearly 86%. In a search towards synthetic modulators of malarial GST(s), 575 compounds belonging to various chemical classes were screened for their effect on crude GST from P. yoelii and 92 compounds belonging to various chemical classes were studied on recombinant GST from P. falciparum. Among all the compounds screened, 83 compounds inhibited/stimulated the enzyme from P. yoelii/P. falciparum to the extent of 40% or more.
Collapse
Affiliation(s)
- Rumana Ahmad
- Division of Biochemistry, Central Drug Research Institute, Lucknow, India
| | | | | | | | | |
Collapse
|
30
|
Periyanayagam K, Nirmala Devi K, Suseela L, Uma A, Ismail M. In vivo antimalarial activity of leaves of Plectranthus amboinicus (lour) spreng on Plasmodium berghei yoelii. J Commun Dis 2008; 40:121-125. [PMID: 19301696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
An invivo study of aqueous extract of the leaves of Plectranthus amboinicus on Plasmodium berghei yoelii was conducted on laboratory infected albino mice and compared with standard drug chloroquine. Reduction of parasitemia at 250 mg/kg and 500 mg/kg of aqueous extract for 24 hrs, 48 hrs, 72 hrs and 96 hrs were determined. The reduction of parasitemia after 96 hrs was 100%, 67.9% and 76.2% for standard, 250 mg/kg and 500 mg/kg of aqueous extract respectively. The isolation of active principle responsible for the reduction of parasitemia may give a promising drug molecule.
Collapse
Affiliation(s)
- K Periyanayagam
- Department of Pharmacognosy, Madurai Medical College, Madurai, 625020, Tamil Nadu, India.
| | | | | | | | | |
Collapse
|
31
|
Iwalewa EO, Omisore NO, Adewunmi CO, Gbolade AA, Ademowo OG, Nneji C, Agboola OI, Daniyan OM. Anti-protozoan activities of Harungana madagascariensis stem bark extract on trichomonads and malaria. J Ethnopharmacol 2008; 117:507-511. [PMID: 18372133 DOI: 10.1016/j.jep.2008.02.019] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2007] [Revised: 01/24/2008] [Accepted: 02/14/2008] [Indexed: 05/26/2023]
Abstract
AIM OF THE STUDY The ethanolic stem bark extract of Harungana madagascariensis (Hypericaceae), (Choisy) Poir were evaluated for their activities on Trichomonas gallinae (Rivolta) Stabler isolated from the pigeon (Columba livia). It was also tested for their anti-malarial activity on N67 Plasmodium yoelii nigeriensis (in vivo) in mice and on Plasmodium falciparum isolates in vitro. MATERIALS AND METHODS The anti-trichomonal screening was performed in vitro using Trichomonas gallinae culture. The minimum lethal concentration (MLC) is the lowest concentration of the test extract in which no motile organisms were observed. The anti-malarial effects were determined in-vivo for suppressive, curative and prophylactic activities in mice receiving a standard inoculum size of 1 x 10(7) (0.2 ml) infected erythrocytes of Plasmodium yoelii nigeriensis intraperitoneally, and the in vitro was performed against 3 isolates of Plasmodium falciparum in a candle jar procedures. RESULTS The IC(50) of the extract and metronidazole (MDZ) (Flagyl) on Trichomonas gallinae at 48 h are 187 and 1.56 microg/ml. The IC(50) of the extract, chloroquine (CQ) and artemether (ART) on Plasmodium falciparum are between 0.052 and 0.517 microg/ml for the extract and 0.021 and 0.0412 microg/ml for ART and CQ, respectively. The actions of the extract in in vivo study on Plasmodium yoelii nigeriensis showed that in both suppressive and prophylactic tests the percentages chemo-suppressive were between 28.6-44.8% and 30.2-78.2% respectively, while only 80 mg/kg of the extract reduced the parasitaemia level when compared to the control and the standard drugs in curative test. CONCLUSIONS Harungana madagascariensis stem bark extract therefore exhibited significant anti-protozoan effects against Trichomonas and Plasmodium both in vivo and in vitro.
Collapse
Affiliation(s)
- E O Iwalewa
- Department of Pharmacology, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Mahmoudi N, Garcia-Domenech R, Galvez J, Farhati K, Franetich JF, Sauerwein R, Hannoun L, Derouin F, Danis M, Mazier D. New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 2008; 52:1215-20. [PMID: 18212104 PMCID: PMC2292524 DOI: 10.1128/aac.01043-07] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2007] [Revised: 10/31/2007] [Accepted: 01/13/2008] [Indexed: 11/20/2022] Open
Abstract
We conducted a quantitative structure-activity relationship (QSAR) study based on a database of 127 compounds previously tested against the liver stage of Plasmodium yoelii in order to develop a model capable of predicting the in vitro antimalarial activities of new compounds. Topological indices were used as structural descriptors, and their relation to antimalarial activity was determined by using linear discriminant analysis. A topological model consisting of two discriminant functions was created. The first function discriminated between active and inactive compounds, and the second identified the most active among the active compounds. The model was then applied sequentially to a large database of compounds with unknown activity against liver stages of Plasmodium. Seventeen drugs that were predicted to be active or inactive were selected for testing against the hepatic stage of P. yoelii in vitro. Antiretroviral, antifungal, and cardiotonic drugs were found to be highly active (nanomolar 50% inhibitory concentration values), and two ionophores completely inhibited parasite development. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed on hepatocyte cultures for all compounds, and none of these compounds were toxic in vitro. For both ionophores, the same in vitro assay as those for P. yoelii has confirmed their in vitro activities on Plasmodium falciparum. A similar topological model was used to estimate the octanol/water partition of each compound. These results demonstrate the utility of the QSAR and molecular topology approaches for identifying new drugs that are active against the hepatic stage of malaria parasites. We also show the remarkable efficacy of some drugs that were not previously reported to have antiparasitic activity.
Collapse
Affiliation(s)
- Nassira Mahmoudi
- Université Pierre et Marie Curie-Paris 6, UMR S511, Paris F-75013, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Guha M, Maity P, Choubey V, Mitra K, Reiter RJ, Bandyopadhyay U. Melatonin inhibits free radical-mediated mitochondrial-dependent hepatocyte apoptosis and liver damage induced during malarial infection. J Pineal Res 2007; 43:372-81. [PMID: 17910606 DOI: 10.1111/j.1600-079x.2007.00488.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
We showed earlier that malarial infection significantly induces liver apoptosis mediated by oxidative stress mechanisms. Thus, a nontoxic antioxidant-antiapoptotic molecule may be beneficial for hepatoprotection. Melatonin remarkably prevents hepatocyte apoptosis in mice induced during malaria as indicated by caspase 3 and TUNEL assays as well as transmission electron microscopy (TEM) of the liver tissue. The mitochondrial apoptotic pathway, which plays a critical role in liver cell death during malarial infection, was almost completely suppressed by melatonin as it corrects both the overexpression of Bax and down-regulation of bcl-2 as revealed by semiquantitative RT-PCR. Fluorometric studies using JC-1 documented that melatonin also restores mitochondrial transmembrane potential (DeltaPsim) in malaria-infected mice liver. The antiapoptotic effect of melatonin is associated with its antioxidant role because melatonin protects liver from oxidative stress induced during malaria by scavenging the hydroxyl radicals, preventing the depletion of reduced glutathione, inhibiting lipid peroxidation and protein carbonyl formation. The effective antioxidant dose of melatonin to protect liver from oxidative stress during malaria is 20 times lower than that of known antioxidants, vitamin C and vitamin E. Apoptosis of hepatocytes during malarial infection is well correlated with dysfunction of the liver while melatonin offers hepatoprotective effects as indicated by different liver function tests. Thus, melatonin may well be effective in combating oxidative stress-induced apoptosis and liver damage during malaria infection.
Collapse
Affiliation(s)
- Mithu Guha
- Division of Infectious Diseases and Immunology, Indian Institute of Chemical Biology, Kolkata, West Bengal, India
| | | | | | | | | | | |
Collapse
|
34
|
Singh C, Sharma U, Saxena G, Puri SK. Orally active antimalarials: Synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice. Bioorg Med Chem Lett 2007; 17:4097-101. [PMID: 17548195 DOI: 10.1016/j.bmcl.2007.05.055] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2007] [Revised: 05/09/2007] [Accepted: 05/18/2007] [Indexed: 10/23/2022]
Abstract
A new series of steroid-based 1,2,4-trioxanes 7a-f, 8a-f and 9b-e have been synthesized and evaluated for their antimalarial activity against multi-drug resistant Plasmodium yoelii in Swiss mice by oral route. The biological activity shows a strong dependence on the size and the nature of the steroidal side chain. Pregnane-based trioxanes 8a-f show better activity profile than trioxanes 7a-f and 9b-e, derived from cholesterol and tigogenine, respectively.
Collapse
Affiliation(s)
- Chandan Singh
- Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow 226001, India.
| | | | | | | |
Collapse
|
35
|
Kumar KA, Garcia CRS, Chandran VR, Van Rooijen N, Zhou Y, Winzeler E, Nussenzweig V. Exposure of Plasmodium sporozoites to the intracellular concentration of potassium enhances infectivity and reduces cell passage activity. Mol Biochem Parasitol 2007; 156:32-40. [PMID: 17714805 DOI: 10.1016/j.molbiopara.2007.07.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2007] [Revised: 07/09/2007] [Accepted: 07/10/2007] [Indexed: 10/23/2022]
Abstract
Malaria sporozoites migrate through several cells prior to a productive invasion that involves the formation of a parasitophorous vacuole (PV) where sporozoites undergo transformation into Exo-erythorcytic forms (EEFs). The precise mechanism leading to sporozoite activation for invasion is unknown, but prior traversal of host cells is required. During cell migration sporozoites are exposed to large shifts in K(+) concentration. We report here that incubation of sporozoites to the intracellular K(+) concentration enhances 8-10 times the infectivity of Plasmodium berghei and 4-5 times the infectivity of Plasmodium yoelli sporozoites for a hepatocyte cell line, while simultaneously decreasing cell passage activity. The K(+) enhancing effect was time and concentration dependent, and was significantly decreased by K(+) channel inhibitors. Potassium-treated P. berghei sporozoites also showed enhanced numbers of EEFs in non-permissive cell lines. Treated sporozoites had reduced infectivity for mice, but infectivity was enhanced upon Kupffer cell depletion. Transcriptional analysis of K(+) treated and control sporozoites revealed a high degree of correlation in their levels of gene expression, indicating that the observed phenotypic changes are not due to radical changes in gene transcription. Only seven genes were upregulated by more than two-fold in K(+) treated sporozoites. The highest level was noted in PP2C, a phosphatase known to dephosphorylate the AKT potassium channel in plants.
Collapse
Affiliation(s)
- Kota Arun Kumar
- Michael Heidelberger Division of Immunology, Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Silveira H, Ramos S, Abrantes P, Lopes LF, do Rosario VE, Abrahamsen MS. Effect of chloroquine on gene expression of Plasmodium yoelii nigeriensis during its sporogonic development in the mosquito vector. Malar J 2007; 6:84. [PMID: 17605769 PMCID: PMC1940257 DOI: 10.1186/1475-2875-6-84] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2007] [Accepted: 07/02/2007] [Indexed: 12/04/2022] Open
Abstract
Background The anti-malarial chloroquine can modulate the outcome of infection during the Plasmodium sporogonic development, interfering with Plasmodium gene expression and subsequently, with transmission. The present study sets to identify Plasmodium genes that might be regulated by chloroquine in the mosquito vector. Methods Differential display RT-PCR (DDRT-PCR) was used to identify genes expressed during the sporogonic cycle that are regulated by exposure to chloroquine. Anopheles stephensi mosquitoes were fed on Plasmodium yoelii nigeriensis-infected mice. Three days post-infection, mosquitoes were fed a non-infectious blood meal from mice treated orally with 50 mg/kg chloroquine. Two differentially expressed Plasmodium transcripts (Pyn_chl091 and Pyn_chl055) were further characterized by DNA sequencing and real-time PCR analysis. Results Both transcripts were represented in Plasmodium EST databases, but displayed no homology with any known genes. Pyn_chl091 was upregulated by day 18 post infection when the mosquito had a second blood meal. However, when the effect of chloroquine on that transcript was investigated during the erythrocytic cycle, no significant differences were observed. Although slightly upregulated by chloroquine exposure the expression of Pyn_chl055 was more affected by development, increasing towards the end of the sporogonic cycle. Transcript abundance of Pyn_chl055 was reduced when erythrocytic stages were treated with chloroquine. Conclusion Chloroquine increased parasite load in mosquito salivary glands and interferes with the expression of at least two Plasmodium genes. The transcripts identified contain putative signal peptides and transmembrane domains suggesting that these proteins, due to their location, are targets of chloroquine (not as an antimalarial) probably through cell trafficking and recycling.
Collapse
Affiliation(s)
- Henrique Silveira
- Centro de Malária e Outras Doenças Tropicais, UEI Malária, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal
| | - Susana Ramos
- Centro de Malária e Outras Doenças Tropicais, UEI Malária, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal
| | - Patrícia Abrantes
- Centro de Malária e Outras Doenças Tropicais, UEI Malária, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal
| | - Luís Filipe Lopes
- Centro de Malária e Outras Doenças Tropicais, UEI Malária, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal
| | - Virgílio E do Rosario
- Centro de Malária e Outras Doenças Tropicais, UEI Malária, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal
| | | |
Collapse
|
37
|
Ma SH, Zheng L, Liu YJ, Guo SY, Feng H, Chen G, Li DM, Wang JC, Cao YM. Plasmodium yoelii: Influence of antimalarial treatment on acquisition of immunity in BALB/c and DBA/2 mice. Exp Parasitol 2007; 116:266-72. [PMID: 17336298 DOI: 10.1016/j.exppara.2007.01.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2006] [Revised: 12/22/2006] [Accepted: 01/12/2007] [Indexed: 11/19/2022]
Abstract
The effect of antimalarial drugs on immune responses to the malaria infection is evaluated in vivo using two experimental self-cured rodent models. BALB/c and DBA/2 mice were infected by Plasmodium yoelii 17XNL and 17XL strains, respectively, and then treated with different doses of antimalarial drugs: chloroquine (228mg/kg or 114mg/kg of the body weight) or artesunate (78mg/kg or 39mg/kg). The effect of antimalarial drugs on host immune responses was evaluated by parasitemia, splenocyte IFN-gamma production level, and parasite-specific IgG level in the serum, however, no significant differences were observed between drug-treated and untreated groups. Moreover, most of the infected mice of all groups showed the ability to resist homologous reinfection (challenged on day 60 post-infection), only a few mice experienced transient, low parasitemia. The rechallenged mice were accompanied by high level of parasite-specific IgG. Therefore, this research implicated that, for BALB/c and DBA/2 mice, chloroquine or artesunate treatment of blood-stage P. yoelii infections does not compromise acquired immunity to malaria in either primary infection or upon rechallenge.
Collapse
Affiliation(s)
- Shi-Hong Ma
- Department of Immunology, College of Basic Medical Sciences, China Medical University, Heping District, Shenyang, China
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Rungruang T, Klosek SK. Chronic steroid administration does not suppress Plasmodium development and maturation. Parasitol Res 2007; 101:1091-5. [PMID: 17557154 DOI: 10.1007/s00436-007-0592-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2007] [Accepted: 05/14/2007] [Indexed: 11/26/2022]
Abstract
The objective of this study was to investigate the influence of constant steroid uptake on the Plasmodium yoelii infection rate and parasite maturation. On the animal model, we examined the effect(s) of dexamethasone (Dx), the general drug used for self-treatment by Thai villagers. Ten female ICR mice were subjected to oral administration of 0.5 mg/kg Dx for 40 days, whereas other ten were given drinking water only before P. yoelii 17X (lethal) strain inoculation. Parasite-infected erythrocytes were verified by Giemsa staining under light microscope. The differences of infectivity and maturation were evaluated by Student's t test. Parasitemia was detected in both groups on day 1 and increased until day 6 with similar infection rates. Significant lower numbers of ring, trophozoite, and schizont stages in the control group at the same time compared to Dx-treated mice were noted. The parasite maturation in infected Dx-treated mice appeared faster in comparison to the control. We conclude that the chronic taking of Dx suppresses the host immunity, without any suppressive effects on the parasite development and maturation, and, on the contrary, increases the development and maturation of P. yoelii.
Collapse
Affiliation(s)
- Thanaporn Rungruang
- Department of Anatomy, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok 10700, Thailand.
| | | |
Collapse
|
39
|
Liu YJ, Wang JC, Feng H, Zhu XT, An CL, Cao YM. [In vitro observation on effect of nitric oxide on exflagellation of Plasmodium yoelii]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2007; 25:206-212. [PMID: 18038779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
OBJECTIVE To observe the effect of nitric oxide (NO) on exflagellation of malaria parasite. METHODS The level of parasitemia and gametocytaemia in DBA/2 mice infected with Plasmodium yoelii 17XL was measured by scanning Giemsa-stained blood smears, and the NO level in culture supernatant of splenocytes was checked using Griess reaction. The mice were injected with different doses of NO donor (NOC5) on day 4 post-infection, and control mice were injected with NOC5 precursor. On day 6 post-infection, mice were injected with NOS inhibitor (L-NMMA), and control mice were injected with D-NMMA and PBS, respectively. Blood samples were collected from tail vein of mice before injection, 30 and 60 min after being injected with NOC5 and NOC5 precursor, 4 and 8 h after being injected with L-NMMA, D-NMMA, and PBS respectively. Exflagellation number of gametocytes in blood culture was counted under microscope. Results The NO level in culture supernatant of splenocytes from mice on day 4 and 6 post-infection was 16.5 mmol/L and 30.4 mmol/L, and exflagellation number was 11.33 and 0.66, respectively. The number of exflagellation in parasitized erythrocytes, obtained from mice on day 4 post-infection, was 5.33 and 2.66, respectively, 30 and 60 min after injection of 1 mg NO donor (NOC5), significantly lower than that of the control (P<0.01). The number of exflagellation in parasitized erythrocytes derived from mice on day 6 post-infection was 1.83, 8 h after the injection of NOS inhibitor (L-NMMA), which was significantly higher than that of the control (P<0.01). CONCLUSION NO is a major effector molecule resulting in natural transmission-blocking of malaria parasite by directly inhibiting exflagellation of male gametocytes.
Collapse
Affiliation(s)
- Ying-jie Liu
- Department of Pathogen Biology, China Medical University, Shenyang 110001, China
| | | | | | | | | | | |
Collapse
|
40
|
Abstract
A new series of side-chain modified 4-aminoquinolines have been synthesized and found active against P. falciparum in vitro and P. yoelli in vivo. Compounds 6, 11, 12, and 19 exhibited superior in vitro activity compared to chloroquine. Selected compounds 6, 12, and 19 exhibited significant suppression in the in vivo assay. These analogs form a complex with hematin and inhibit the beta-hematin formation, suggesting that this class of compounds act on a heme polymerization target.
Collapse
Affiliation(s)
- V Raja Solomon
- Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow 226 001, India
| | | | | | | | | |
Collapse
|
41
|
Abstract
Plasmodium spp. cause the worst parasitic diseases in humans and evade host immunity in complicated ways. Activated catabolism of tryptophan in dendritic cells is thought to suppress immunity, which is mediated by an inducible rate-limiting enzyme of tryptophan catabolism, indoleamine 2,3 dioxygenase (IDO), via both tryptophan depletion and production of toxic metabolites. In various infections, including malaria, IDO is known to be activated but its biological significance is unclear; therefore, we investigated whether malaria parasites induce IDO to suppress host immune responses. We found that enzymatic activity of IDO was elevated systematically in our mouse malaria model, and was abolished by in vivo IDO inhibition with 1-methyl tryptophan. Experimental infection with Plasmodium yoelii showed that IDO inhibition slightly suppressed parasite density in association with enhanced proliferation and IFN-gamma production by CD4+ T cells in response to malaria parasites. Our observations suggest that induction of IDO is one of the immune mechanisms of malaria parasites.
Collapse
Affiliation(s)
- K Tetsutani
- Kyushu University Graduate School of Medicine, Department of Parasitology, 3-1-1, Maidashi, Fukuoka, 812-0054, Japan.
| | | | | | | | | |
Collapse
|
42
|
Lazaro JEH, Nitcheu J, Mahmoudi N, Ibana JA, Mangalindan GC, Black GP, Howard-Jones AG, Moore CG, Thomas DA, Mazier D, Ireland CM, Concepcion GP, Murphy PJ, Diquet B. Antimalarial activity of crambescidin 800 and synthetic analogues against liver and blood stage of Plasmodium sp. J Antibiot (Tokyo) 2007; 59:583-90. [PMID: 17136890 DOI: 10.1038/ja.2006.78] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Structural features associated with the antimalarial activity of the marine natural product crambescidin 800 were studied using synthetic analogues of the related compound ptilomycalin A. The study suggests that the guanidine moiety is cytotoxic, whereas the spermidine-containing aliphatic chain increases activity. The most active analogue, compound 11, had in vitro activity against Plasmodium falciparum strain 3D7 (IC50=490 nM) that was stronger than the in vitro activity against murine L5178Y cells (IC50 = 8.5-59 microM). In vitro growth inhibition of liver stages of P. yoelii yoelii in mouse hepatocytes was observed (IC50 = 9.2 microM). The compound did not significantly prolong median survival time after a single subcutaneous administration of 80 mg/kg in P. berghei-infected mice. Compound 11 did not cause DNA fragmentation in an in vitro micronucleus assay.
Collapse
Affiliation(s)
- J Enrico H Lazaro
- Marine Science Institute, University of the Philippines, Diliman 1101, Quezon City, Philippines.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
New 6-arylvinyl- and 6-adamantylvinyl-substituted 1,2,4-trioxanes (13a-g and 14a,b) have been prepared and evaluated for antimalarial activity against multidrug resistant Plasmodium yoelii nigeriensis in mice by both oral and intramuscular routes. While all the 6-arylvinyl-substituted trioxanes, 13a-f, showed promising activity, none of the 6-adamantylvinyl-substituted trioxanes, 13g and 14a,b, exhibited significant activity. Trioxane, 13f, the most active compound of the series, provided 100% and 80% protection to malaria-infected mice at 48 mg/kg x 4 days and 24 mg/kg x 4 days, respectively, by oral route. In this model, beta-arteether (3) provided 100% protection at 48 mg/kg x 4 days and only 20% protection at 24 mg/kg x 4 days. Trioxane 13f also showed complete suppression of parasitaemia at 10 mg/kg x 4 days by oral route in rhesus monkeys infected with P. cynomolgi. None of these trioxanes, except 13f, showed significant activity by the intramuscular route.
Collapse
Affiliation(s)
- Chandan Singh
- Division of Medicinal and Process Chemistry and Division of Parasitology, Central Drug Research Institute, Lucknow-226001, India.
| | | | | | | |
Collapse
|
44
|
Mohd Ridzuan MAR, Ruenruetai U, Noor Rain A, Khozirah S, Zakiah I. Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice. Trop Biomed 2006; 23:140-6. [PMID: 17322815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Malaria is a disease which is still endemic and has become a disastrous scourge because of the emergence of antimalarial drug resistant Plasmodium falciparum. A new approach in addressing this is in developing a combination drug. This study is to show the enhancement of antimalarial properties, when single compound, goniothalamin combine with standard drug, chloroquine. Based on 4 Day Test, percentage of parasite growth on treated infected mice were determined. Oral treatment with 1 mg/kg BW of chloroquine on experimental mice suppressed 70% and 76.7% of both Plasmodium yoelii and Plasmodium berghei, respectively. The infection of P. berghei in mice was inhibited less than 50% by goniothalamin individual treatment at all doses in this study. About 27.8% and 18.5% inhibition of infection were observed in P. yoelii infected mice treated with 30 mg/kg and 60 mg/kg of goniothalamin respectively and the suppression exceed more than 50% at higher doses (90 and 120 mg/kg). Combination of 1 mg/kg chloroquine with either 30 mg/kg or 60 mg/kg of goniothalamin decreased the parasitemia of P. yoelii infected mice more than 90% and prolong the survival up to 100% after treatment. Similar treatment to P. berghei infected mice only shows about 60% reduction of parasitemia. The study findings showed that antimalarial property of goniothalamin was enhanced by combination with chloroquine at lower dose of each drug.
Collapse
Affiliation(s)
- M A R Mohd Ridzuan
- Herbal Medicine Research Center, Institute for Medical Research, Kuala Lumpur, Malaysia.
| | | | | | | | | |
Collapse
|
45
|
Carraz M, Jossang A, Franetich JF, Siau A, Ciceron L, Hannoun L, Sauerwein R, Frappier F, Rasoanaivo P, Snounou G, Mazier D. A plant-derived morphinan as a novel lead compound active against malaria liver stages. PLoS Med 2006; 3:e513. [PMID: 17194195 PMCID: PMC1716192 DOI: 10.1371/journal.pmed.0030513] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2006] [Accepted: 10/25/2006] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND The global spread of multidrug-resistant malaria parasites has led to an urgent need for new chemotherapeutic agents. Drug discovery is primarily directed to the asexual blood stages, and few drugs that are effective against the obligatory liver stages, from which the pathogenic blood infection is initiated, have become available since primaquine was deployed in the 1950s. METHODS AND FINDINGS Using bioassay-guided fractionation based on the parasite's hepatic stage, we have isolated a novel morphinan alkaloid, tazopsine, from a plant traditionally used against malaria in Madagascar. This compound and readily obtained semisynthetic derivatives were tested for inhibitory activity against liver stage development in vitro (P. falciparum and P. yoelii) and in vivo (P. yoelii). Tazopsine fully inhibited the development of P. yoelii (50% inhibitory concentration [IC50] 3.1 muM, therapeutic index [TI] 14) and P. falciparum (IC50 4.2 muM, TI 7) hepatic parasites in cultured primary hepatocytes, with inhibition being most pronounced during the early developmental stages. One derivative, N-cyclopentyl-tazopsine (NCP-tazopsine), with similar inhibitory activity was selected for its lower toxicity (IC50 3.3 muM, TI 46, and IC50 42.4 muM, TI 60, on P. yoelii and P. falciparum hepatic stages in vitro, respectively). Oral administration of NCP-tazopsine completely protected mice from a sporozoite challenge. Unlike the parent molecule, the derivative was uniquely active against Plasmodium hepatic stages. CONCLUSIONS A readily obtained semisynthetic derivative of a plant-derived compound, tazopsine, has been shown to be specifically active against the liver stage, but inactive against the blood forms of the malaria parasite. This unique specificity in an antimalarial drug severely restricts the pressure for the selection of drug resistance to a parasite stage limited both in numbers and duration, thus allowing researchers to envisage the incorporation of a true causal prophylactic in malaria control programs.
Collapse
Affiliation(s)
- Maëlle Carraz
- Laboratoire de Chimie et Biochimie des Substances Naturelles, Muséum National d'Histoire Naturelle, Paris, France
- Inserm U511, Université Pierre et Marie Curie-Paris, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
- Université Pierre et Marie Curie-Paris, Faculté de Médecine Pitié-Salpêtrière, Paris, France
| | - Akino Jossang
- Laboratoire de Chimie et Biochimie des Substances Naturelles, Muséum National d'Histoire Naturelle, Paris, France
| | - Jean-François Franetich
- Inserm U511, Université Pierre et Marie Curie-Paris, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
- Université Pierre et Marie Curie-Paris, Faculté de Médecine Pitié-Salpêtrière, Paris, France
| | - Anthony Siau
- Inserm U511, Université Pierre et Marie Curie-Paris, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
- Université Pierre et Marie Curie-Paris, Faculté de Médecine Pitié-Salpêtrière, Paris, France
| | - Liliane Ciceron
- Inserm U511, Université Pierre et Marie Curie-Paris, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
- Université Pierre et Marie Curie-Paris, Faculté de Médecine Pitié-Salpêtrière, Paris, France
| | - Laurent Hannoun
- AP HP, Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France
| | - Robert Sauerwein
- University Medical Center St. Radboud, Department of Medical Microbiology, Nijmegen, The Netherlands
| | - François Frappier
- Laboratoire de Chimie et Biochimie des Substances Naturelles, Muséum National d'Histoire Naturelle, Paris, France
| | - Philippe Rasoanaivo
- Laboratoire de Pharmacognosie Appliquée aux Maladies Infectieuses, Institut Malgache de Recherches Appliquées, Antananarivo, Madagascar
| | - Georges Snounou
- Laboratoire de Parasitologie Comparée et Modèles Expérimentaux, Muséum National d'Histoire Naturelle, Paris, France
| | - Dominique Mazier
- Inserm U511, Université Pierre et Marie Curie-Paris, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
- Université Pierre et Marie Curie-Paris, Faculté de Médecine Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
46
|
Ono T, Tadakuma T, Rodriguez A. Plasmodium yoelii yoelii 17XNL constitutively expressing GFP throughout the life cycle. Exp Parasitol 2006; 115:310-3. [PMID: 17049517 PMCID: PMC1779952 DOI: 10.1016/j.exppara.2006.09.008] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2006] [Revised: 09/06/2006] [Accepted: 09/08/2006] [Indexed: 11/23/2022]
Abstract
Plasmodium yoelii is a rodent parasite commonly used as a model to study malaria infection. It is the preferred model parasite for liver-stage immunological studies and is also widely used to study hepatocyte, erythrocyte and mosquito infection. We have generated a P. yoelii yoelii 17XNL line that is stably transfected with the green fluorescent protein (gfp) gene. This parasite line constitutively expresses high levels of GFP during the complete parasite life cycle including liver, blood and mosquito stages. These fluorescent parasites can be used in combination with fluorescence activated cell sorting or live microscopy for a wide range of experimental applications.
Collapse
Affiliation(s)
- Takeshi Ono
- New York University School of Medicine, Department of Medical Parasitology, 341 E 25 street, New York, NY 10010, USA
- Department of Parasitology and Immunology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Takushi Tadakuma
- Department of Parasitology and Immunology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Ana Rodriguez
- New York University School of Medicine, Department of Medical Parasitology, 341 E 25 street, New York, NY 10010, USA
- *Corresponding author. e-mail address: , Phone: (212) 263 6757, Fax: (212) 263 8116
| |
Collapse
|
47
|
Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006; 2:415-6. [PMID: 16816845 DOI: 10.1038/nchembio806] [Citation(s) in RCA: 204] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2006] [Accepted: 06/16/2006] [Indexed: 11/08/2022]
Abstract
The high cost and protracted time line of new drug discovery are major roadblocks to creating therapies for neglected diseases. To accelerate drug discovery we created a library of 2,687 existing drugs and screened for inhibitors of the human malaria parasite Plasmodium falciparum. The antihistamine astemizole and its principal human metabolite are promising new inhibitors of chloroquine-sensitive and multidrug-resistant parasites, and they show efficacy in two mouse models of malaria.
Collapse
Affiliation(s)
- Curtis R Chong
- Department of Pharmacology and Molecular Sciences. The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| | | | | | | | | |
Collapse
|
48
|
Tripathi R, Jefford CW, Dutta GP. Blood schizontocidal activity of selected 1,2,4-trioxanes (Fenozans) against the multidrug-resistant strain of Plasmodium yoelii nigeriensis (MDR) in vivo. Parasitology 2006; 133:1-9. [PMID: 16764736 DOI: 10.1017/s0031182006009905] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2005] [Revised: 09/09/2005] [Accepted: 01/04/2006] [Indexed: 11/07/2022]
Abstract
Blood schizontocidal activity of 10 selected cis-fused cyclopenteno-1,2,4-trioxanes (namely Fenozan compound nos 6, 7, 11, 27, 32, 39, 44, 45, 48 and 51) have been re-investigated to establish their curative doses against the multidrug-resistant Plasmodium yoelii nigeriensis strain, which is lethal in Swiss mice. Freshly prepared formulations of these compounds prepared either in neutral groundnut (peanut) oil or in dimethyl sulfoxide (DMSO)-Tween-water, were compared for their antimalarial activity. Only 2 compounds, namely Fenozan derivatives 11 and 45, formulated in neutral groundnut oil for oral administration, showed highest activity with 100% cure rate in MDR P. yoelii nigeriensis-infected mice, while the DMSO-Tween-water formulations were inactive. Fenozan-48 produced 72.2% cure, when administered orally in groundnut oil (formulation) while its DMSO-Tween formulation was inactive. In the case of Fenozan 7, the oil and DMSO-Tween formulations produced 92.3 and 76.0% cures respectively. Fenozan derivatives nos 6, 27, 32, 39, 44 and 51 were not protective either in groundnut oil or DMSO-Tween oral formulations. The present study has applied more rigorous criteria for selection of active compounds, and has identified the 3,3-spirocyclopentane derivative Fenozan 11, and the 3,3-spirohydropyran derivative Fenozan 45, as potential blood schizontocides which can completely eliminate multidrug-resistant malaria infection in mice. Both these compounds are candidates for pre-clinical development. The present study advocates the preferred use of an oil vehicle for oral evaluation of potential antimalarial trioxanes/fenozans instead of the DMSO formulation, which gives inferior curative efficacy.
Collapse
Affiliation(s)
- R Tripathi
- Division of Parasitology, Central Drug Research Institute, Lucknow, India.
| | | | | |
Collapse
|
49
|
Abstract
The incidence of malaria is increasing, and there is an urgent need to identify new drug targets for both prophylaxis and chemotherapy. Potential new drug targets include Plasmodium proteases that play critical roles in the parasite life cycle. We have previously shown that the major surface protein of Plasmodium sporozoites, the circumsporozoite protein (CSP), is proteolytically processed by a parasite-derived cysteine protease, and this processing event is temporally associated with sporozoite invasion of host cells. E-64, a cysteine protease inhibitor, inhibits CSP processing and prevents invasion of host cells in vitro and in vivo. Here we tested allicin, a cysteine protease inhibitor found in garlic extracts, for its ability to inhibit malaria infection. At low concentrations, allicin was not toxic to either sporozoites or mammalian cells. At these concentrations, allicin inhibited CSP processing and prevented sporozoite invasion of host cells in vitro. In vivo, mice injected with allicin had decreased Plasmodium infections compared to controls. When sporozoites were treated with allicin before injection into mice, malaria infection was completely prevented. We also tested allicin on erythrocytic stages and found that a 4-day regimen of allicin administered either orally or intravenously significantly decreased parasitemias and increased the survival of infected mice by 10 days. Together, these experiments demonstrate that the same cysteine protease inhibitor can target two different life cycle stages in the vertebrate host.
Collapse
Affiliation(s)
- Alida Coppi
- Department of Medical Parasitology, New York University School of Medicine, 341 East 25th Street, New York, NY 10010, USA
| | | | | | | |
Collapse
|
50
|
Singh C, Malik H, Puri SK. Orally Active 1,2,4-Trioxanes: Synthesis and Antimalarial Assessment of a New Series of 9-Functionalized 3-(1-Arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against Multi-Drug-Resistant Plasmodium yoelii nigeriensis in Mice. J Med Chem 2006; 49:2794-803. [PMID: 16640340 DOI: 10.1021/jm051130r] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Using easily accessible keto-trioxanes 7a-g as the starting materials, a series of new variously functionalized 1,2,4-trioxanes 10-36 have been prepared and evaluated for antimalarial activity against multi-drug-resistant Plasmodium yoelii nigeriensis in mice in the dose range of 24 mg/kg x 4 days to 96 mg/kg x 4 days by oral route. Trioxanes 10, 12, 14, 16, 18, 20, and 22 have shown promising antimalarial activity. Trioxanes 14 and 18, the two most active compounds of the series, provide 100% and 60% protection at 48 mg/kg x 4 days and 24 mg/kg x 4 days, respectively. In this model beta-arteether provides 100% and 20% protection at 48 mg/kg x 4 days and 24 mg/kg x 4 days, respectively.
Collapse
Affiliation(s)
- Chandan Singh
- Division of Medicinal & Process Chemistry, Central Drug Research Institute, Lucknow-226001, India.
| | | | | |
Collapse
|